STREAM is a collaboration of researchers who share a common set of principles about the goals and methods for studying clinical translation. We apply empirical and philosophical tools for addressing scientific, ethical, and policy challenges in the development and translation of health technologies. Our members work in ethics, epidemiology, biology, psychology, and various medical specialties. The network is centered at McGill University, and has affiliates throughout North America and abroad.
Kimmelman J, Waligora M, Lynch HF. Participant Protection in Phase 1 Pediatric Cancer Trials. JAMA Pediatrics. November 2018.
Kimmelman J. Better to be in The Placebo Arm for Trials of Neurological Therapies?. Cell Transplantation, June 1, 2018.
Kimmelman J, Tannock, I. The paradox of precision medicine. Nature Reviews Clinical Oncology, April 19, 2018.
London A, Kimmelman J. Clinical Trials in Medical Center Advertising, JAMA Oncology, April 5, 2018.
Companion opinion piece: Cancer centers sell out science when they advertise clinical trials as treatment, STAT, April 25, 2018.
Carlisle B, Federico C, Kimmelman J. Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval, The BMJ, March 20, 2018.
Jonathan Kimmelman interviewed by Radio Canada about a controversial pediatric cancer study conducted at Montreal's Ste-Justine Hospital.
Jonathan Kimmelman quoted in NPR: All Things Considered, on medical researchers' ability to make predictions about study outcomes.
Jonathan Kimmelman quoted in Dallas News, on the drawbacks of patient-funded clinical trials.
Jonathan Kimmelman quoted in Bloomberg, on the ethics of self-experimentation.
Jonathan Kimmelman quoted in WJCT, on the unrealistic expectations created by cancer center clinical trial advertisements.
Jonathan Kimmelman quoted in the National Post, on the ethics of synthetic human embryos.
Science coverage of research co-authored by doctoral candidate Carole Federico and Jonathan Kimmelman, on reliability of animal efficacy data.
Jonathan Kimmelman quoted in National Post, on why patients deserve post-trial access to drugs they appear to have benefited from.